VIRTUS INVESTMENT ADVISERS INC
Q3 2026 Form 13-F
HARTFORD, CONNECTICUT
CIK 0000019481
· CRD 106982
· SEC-registered investment adviser
Holdings reported by
NFJ INVESTMENT GROUP LLC since Q2 2021
, Virtus ETF Advisers LLC since Q1 2025
, DUFF & PHELPS INVESTMENT MANAGEMENT CO since Q1 2016
and 7 more
$452.8M Reported Value Total
VIRTUS INVESTMENT ADVISERS, LLC reports 106 total accounts under management (AUM). There are 106 discretionary accounts valued at $51,744,428,475, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Source: Form ADV filed 2026-06-30
Reported value
$452.8M
Quarter over quarter
-2.8%
Holdings
458
Top-10 concentration
9.6%
Holdings reported by
- NFJ INVESTMENT GROUP LLC · since Q2 2021
- Virtus ETF Advisers LLC · since Q1 2025
- DUFF & PHELPS INVESTMENT MANAGEMENT CO · since Q1 2016
- ZEVENBERGEN CAPITAL INVESTMENTS LLC · since Q3 2022
- Ceredex Value Advisors LLC · since Q1 2025
- Sustainable Growth Advisers LP · since Q3 2019
- INFRASTRUCTURE CAPITAL ADVISORS LLC · since Q1 2025
- Virtus Fixed Income Advisers LLC · since Q2 2025
- Westchester Capital Management LLC · since Q4 2021
- Silvant Capital Management LLC · since Q3 2022
- Voya Investment Management LLC · Q1 2024 – Q1 2026 · declared by one filing
- REAVES W H & CO INC · Q4 2025 – Q1 2026 · declared by one filing
- KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC · Q4 2015 – Q1 2026
- VONTOBEL ASSET MANAGEMENT INC · Q1 2016 – Q4 2023 · declared by one filing
- Newfleet Asset Management LLC · Q4 2020 – Q2 2022 · declared by one filing
- Rampart Investment Management Company LLC (not a 13F filer in our records) · Q4 2014 – Q4 2020 · declared by one filing
- Thomas J Herzfeld Advisors Inc · Q1 2016 – Q2 2020 · declared by one filing
- HORIZON KINETICS ASSET MANAGEMENT LLC · Q1 2019 – Q2 2020 · declared by one filing
- Horizon Kinetics LLC · Q1 2016 – Q4 2018 · declared by one filing
- SASCO CAPITAL INC CT · Q2 2016 – Q4 2017 · declared by one filing
Key People
Form ADV owners & control persons
Daphne Tippens Chisolm
VICE PRESIDENT, SENIOR COUNSEL AND ASSISTANT SECRETARY
Jennifer Seymour Fromm
VICE PRESIDENT, SENIOR COUNSEL AND ASSISTANT SECRETARY
David George Hanley
TREASURER
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q3 2026 13F record
Q3 2026 13F filing summary
| Period of report | September 30, 2026 |
|---|---|
| Filed | November 12, 2026 |
| Form | 13F-HR |
| Reported value | $452.8M |
| Positions | 458 |
| Change in reported value | +5.5% |
| New positions | 45 |
| Exited positions | 50 |
| Position turnover | 18.7% |
| Top-10 concentration | 9.6% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 12, 2026
|
458 | $452.8M |
|
Q2 2026 13F
Filed Aug 11, 2026
|
463 | $429.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
450 | $362.5M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
461 | $367.9M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
440 | $349.3M |
|
Q2 2025 13F
Filed Aug 13, 2025
|
439 | $295.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
470 | $367.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
293 | $127.6M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
269 | $127.1M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
253 | $118.2M |
|
Q1 2024 13F
Filed May 16, 2024
|
264 | $139.9M |
|
Q4 2023 13F
Filed Feb 15, 2024
|
346 | $133.5M |
|
Q3 2023 13F
Filed Nov 8, 2023
|
242 | $147.0M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
259 | $147.2M |
|
Q1 2023 13F
Filed May 15, 2023
|
273 | $142.8M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
320 | $150.0M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
375 | $217.6M |
30 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2026
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | MRNA MODERNA INC | $6.5M | 1.44% |
| 2 | IOVA IOVANCE BIOTHERAPEUTICS INC | $6.1M | 1.35% |
| 3 | REGN REGENERON PHARMACEUTICALS | $4.2M | 0.92% |
| 4 | GILD GILEAD SCIENCES INC | $4.1M | 0.91% |
| 5 | AMGN AMGEN INC | $4.0M | 0.89% |
| 6 | VRTX VERTEX PHARMACEUTICALS INC | $4.0M | 0.89% |
| 7 | OMER OMEROS CORP | $3.7M | 0.81% |
| 8 | INCY INCYTE CORP | $3.7M | 0.81% |
| 9 | BMRN BIOMARIN PHARMACEUTICAL INC | $3.6M | 0.81% |
| 10 | VSTM VERASTEM INC | $3.3M | 0.73% |
| 11 | PGEN PRECIGEN INC | $3.2M | 0.72% |
| 12 | OKTA OKTA INC | $2.9M | 0.65% |
| 13 | MRVL MARVELL TECHNOLOGY INC | $2.9M | 0.64% |
| 14 | HALO HALOZYME THERAPEUTICS INC | $2.7M | 0.59% |
| 15 | HPE HEWLETT PACKARD ENTERPRISE C | $2.7M | 0.59% |
| 16 | ZLAB ZAI LAB LTD | $2.6M | 0.57% |
| 17 | AMD ADVANCED MICRO DEVICES INC | $2.6M | 0.57% |
| 18 | RIGL RIGEL PHARMACEUTICALS INC | $2.5M | 0.55% |
| 19 | MU MICRON TECHNOLOGY INC | $2.5M | 0.55% |
| 20 | KNSA KINIKSA PHARMACEUTICALS INTL | $2.4M | 0.54% |
Values as reported on the Q3 2026 Form 13F. Every position is in the holdings table below.